Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD

3.99  -0.19 (-4.55%)

After market: 4.0099 +0.02 (+0.5%)

Fundamental Rating

3

Taking everything into account, ARDX scores 3 out of 10 in our fundamental rating. ARDX was compared to 561 industry peers in the Biotechnology industry. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative. ARDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARDX had negative earnings in the past year.
ARDX had a negative operating cash flow in the past year.
ARDX had negative earnings in each of the past 5 years.
In the past 5 years ARDX always reported negative operating cash flow.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -13.11%, ARDX belongs to the best of the industry, outperforming 83.07% of the companies in the same industry.
With a decent Return On Equity value of -36.91%, ARDX is doing good in the industry, outperforming 72.01% of the companies in the same industry.
Industry RankSector Rank
ROA -13.11%
ROE -36.91%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 84.59%, ARDX belongs to the best of the industry, outperforming 87.52% of the companies in the same industry.
In the last couple of years the Gross Margin of ARDX has remained more or less at the same level.
ARDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARDX has more shares outstanding
The debt/assets ratio for ARDX is higher compared to a year ago.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.35, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
ARDX's Altman-Z score of 0.35 is fine compared to the rest of the industry. ARDX outperforms 65.78% of its industry peers.
A Debt/Equity ratio of 1.04 is on the high side and indicates that ARDX has dependencies on debt financing.
ARDX's Debt to Equity ratio of 1.04 is on the low side compared to the rest of the industry. ARDX is outperformed by 78.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACC10.24%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

ARDX has a Current Ratio of 4.12. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARDX (4.12) is comparable to the rest of the industry.
ARDX has a Quick Ratio of 3.81. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.81, ARDX is in line with its industry, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 3.81
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

ARDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.36%, which is quite impressive.
The Revenue has grown by 127.34% in the past year. This is a very strong growth!
The Revenue has been growing by 129.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.55%
Revenue 1Y (TTM)127.34%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%61.04%

3.2 Future

ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.30% yearly.
ARDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.91% yearly.
EPS Next Y-138.35%
EPS Next 2Y65.39%
EPS Next 3Y81.63%
EPS Next 5Y52.3%
Revenue Next Year12.15%
Revenue Next 2Y21.7%
Revenue Next 3Y23.7%
Revenue Next 5Y21.91%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 33.29, which means the current valuation is very expensive for ARDX.
ARDX's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARDX is cheaper than 90.02% of the companies in the same industry.
ARDX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 33.29
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

ARDX's earnings are expected to grow with 81.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.39%
EPS Next 3Y81.63%

More info and screens

0

5. Dividend

5.1 Amount

ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (5/21/2025, 8:00:00 PM)

After market: 4.0099 +0.02 (+0.5%)

3.99

-0.19 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners64.68%
Inst Owner Change8.18%
Ins Owners1.84%
Ins Owner Change10.03%
Market Cap951.06M
Analysts86.67
Price Target10.52 (163.66%)
Short Float %12.83%
Short Ratio5.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)138.42%
Min EPS beat(2)-46.66%
Max EPS beat(2)323.5%
EPS beat(4)3
Avg EPS beat(4)101.46%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)70.96%
EPS beat(12)9
Avg EPS beat(12)545.42%
EPS beat(16)10
Avg EPS beat(16)407.06%
Revenue beat(2)1
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-7.8%
Max Revenue beat(2)3.56%
Revenue beat(4)3
Avg Revenue beat(4)9.35%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)30.48%
Revenue beat(8)6
Avg Revenue beat(8)31.01%
Revenue beat(12)10
Avg Revenue beat(12)33.16%
Revenue beat(16)12
Avg Revenue beat(16)28.18%
PT rev (1m)-5.81%
PT rev (3m)-2.25%
EPS NQ rev (1m)-54.86%
EPS NQ rev (3m)-58.8%
EPS NY rev (1m)-57.54%
EPS NY rev (3m)-172.71%
Revenue NQ rev (1m)-5.1%
Revenue NQ rev (3m)1.67%
Revenue NY rev (1m)-2.67%
Revenue NY rev (3m)-2.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.29
P/S 2.63
P/FCF N/A
P/OCF N/A
P/B 6.53
P/tB 6.53
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)0.12
Fwd EY3%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS1.52
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.11%
ROE -36.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.59%
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score3
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.18%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 3.81
Altman-Z 0.35
F-Score3
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.55%
EPS Next Y-138.35%
EPS Next 2Y65.39%
EPS Next 3Y81.63%
EPS Next 5Y52.3%
Revenue 1Y (TTM)127.34%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%61.04%
Revenue Next Year12.15%
Revenue Next 2Y21.7%
Revenue Next 3Y23.7%
Revenue Next 5Y21.91%
EBIT growth 1Y35.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.47%
EBIT Next 3Y99.5%
EBIT Next 5Y62.75%
FCF growth 1Y44.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.49%
OCF growth 3YN/A
OCF growth 5YN/A